Ayala Pharmaceuticals (ADXS) News Today $0.03 0.00 (0.00%) (As of 12/20/2024 03:31 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)December 14, 2024 | americanbankingnews.comAyala unit expands cold storage networkSeptember 4, 2024 | msn.comAyala explores minority stake sale in AC Health, sources sayAugust 1, 2024 | msn.comAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsMay 9, 2024 | globenewswire.comImmunome: An Oncology Powerhouse In The MakingApril 2, 2024 | seekingalpha.comAyala Pharmaceuticals Announces Completion of Sale of AL102 to ImmunomeMarch 26, 2024 | globenewswire.comIMNM Oct 2024 22.500 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 putMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 45.000 callMarch 16, 2024 | finance.yahoo.comImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsFebruary 20, 2024 | businesswire.comAdvaxis Executes Strategic Unregistered Equity SalesFebruary 10, 2024 | msn.comAdvaxis Announces Definitive Agreement with Ayala PharmaceuticalsFebruary 7, 2024 | msn.comImmunome to buy AL102, a phase 3 asset for treatment of desmoid tumorsFebruary 6, 2024 | msn.comImmunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala PharmaceuticalsFebruary 6, 2024 | finance.yahoo.comAyala Pharmaceuticals Inc Ordinary Shares ADXSNovember 24, 2023 | morningstar.comAyala Pharmaceuticals: Fiscal Q4 Earnings SnapshotNovember 20, 2023 | sfgate.comLadenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS)November 17, 2023 | msn.comAyala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023October 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Closing of Merger with BiosightOctober 19, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Inc (ADXS)August 3, 2023 | investing.comAyala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023August 1, 2023 | finance.yahoo.comAyala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementJuly 27, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid TumorsJuly 5, 2023 | finance.yahoo.comUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingJune 5, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 23, 2023 | finance.yahoo.comArmando AyalaMay 20, 2023 | health.usnews.comAyala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 27, 2023 | finance.yahoo.comAyala Pharmaceuticals, Inc. (ADXS)April 13, 2023 | uk.finance.yahoo.comHubei Biocause PharmaceuticalApril 12, 2023 | forbes.comAyala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring CommitteeMarch 3, 2023 | finance.yahoo.comAyala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022February 10, 2023 | finance.yahoo.comAdvaxis and Ayala Pharmaceuticals Complete MergerJanuary 19, 2023 | finance.yahoo.comAdvaxis, Inc. (ADXS) Stock Historical Prices & Data - Yahoo FinanceDecember 25, 2022 | finance.yahoo.comForm 8-K Advaxis, Inc. For: Oct 18 - StreetInsider.comOctober 20, 2022 | streetinsider.comRedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate - Yahoo FinanceOctober 20, 2022 | finance.yahoo.comADVAXIS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure (form 8-K) - Marketscreener.comOctober 19, 2022 | marketscreener.comWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session - - BenzingaOctober 19, 2022 | benzinga.comAYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders - Business WireOctober 19, 2022 | businesswire.comAyala, Advaxis Merge - Baystreet.caOctober 19, 2022 | baystreet.caAyala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS - MarketWatchOctober 19, 2022 | marketwatch.comAyala Pharmaceuticals and Advaxis Enter into Merger Agreement - Yahoo FinanceOctober 19, 2022 | finance.yahoo.comAyala stock rises 16% on all-stock merger with Advaxis to focus on cancer drugs - Seeking AlphaOctober 19, 2022 | seekingalpha.comAdvaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswireOctober 19, 2022 | globenewswire.comRich Insights into the Metastatic Urothelial Carcinoma Clinical Trial Analysis Featuring 40+ Companies and Therapies | DelveInsight - GlobeNewswireOctober 17, 2022 | globenewswire.comHerbal Medicinal Products Market Is Expected to Grasp the Value of USD 177.65 Billion with Growing CAGR of 6.83% by 2029, Size, Shares, Trends, Growth and Revenue Outlook - GlobeNewswireOctober 13, 2022 | globenewswire.comBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - Yahoo FinanceOctober 4, 2022 | finance.yahoo.comBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - BenzingaOctober 4, 2022 | benzinga.com Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. ADXS Media Mentions By Week ADXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADXS News Sentiment▼0.000.60▲Average Medical News Sentiment ADXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADXS Articles This Week▼00▲ADXS Articles Average Week Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lixte Biotechnology News Aditxt News Fresh Tracks Therapeutics News Creative Medical Technology News Oragenics News Aptorum Group News Synaptogenix News Hepion Pharmaceuticals News InMed Pharmaceuticals News Protagenic Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADXS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
